MedWatch

Pharmacosmos beats market leader in new study - rival dismisses conclusions

Danish drug group Pharmacosmos claims to have proven its product's superiority over the rival from Swiss Vifor, the world's largest company in in iron deficiency therapy. Vifor rejects the study results.

Foto: Pharmacosmos

Danish Pharmacosmos hopes to take market shares from its Swiss rival Vifor Pharma, the world's largest actor in the market for iron deficiency therapy, which is also the focus of the Danish drug group.

Pharmacosmos' hope is fueled by recent data from a phase III program that, for the first time, directly compared the Danish company's product Monofer to the market leader Ferinject (ferric carboxymaltose).

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier